Practice Point 4.3.1:
The choice of GLP-1 RA should prioritize agents with documented cardiovascular benefits.

Data from the forthcoming FLOW trial are also awaited.

Practice Point 4.3.3:
GLP-1 RA should not be used in combination with DPP-4 inhibitors.

Practice Point 4.3.4:
The risk of hypoglycemia is generally low with GLP-1 RA when used alone, but risk is increased when GLP-1 RA is used concomitantly with other medications such as sulfonylureas or insulin. The doses of sulfonylurea and/or insulin may need to be reduced.

Practice Point 4.3.2:
To minimize gastrointestinal side effects, start with a low dose of GLP-1 RA, and titrate up slowly.

Diabetes in CKD: Visual Guidelines